Clario names Christopher Fikry, M.D. Chief Executive Officer
PHILADELPHIA, PA — June 7, 2022 — Clario, the global leader in evidence generation technology for hybrid, decentralized and site-based clinical trials, announced today that Joe Eazor, Chief Executive Officer (CEO), is retiring, and will continue to support Clario as a member of the Board of Directors. Christopher Fikry, M.D. has been appointed by the Board of Directors as the new CEO of Clario.
Christopher will join Clario in July 2022, transitioning from his current role as President of Analytical Services Division at Thermo Fisher Scientific. Christopher previously served as head of Global Lab Services for PPD and held senior executive roles at Novartis and Quest Laboratories. Christopher shares a commitment with biopharmaceutical R&D teams to deliver better healthcare options to patients as well as a commitment to providing high-quality service.
Clario’s Board of Directors warmly welcomes Christopher to Clario, as the company continues to evolve and strengthen its market leadership. In making the announcement, the Board shared, “Christopher’s long experience and commitment to supporting global biopharma and biotech companies, our key customers, in bringing new medicines to patients faster, safer and more cost effectively is right in line with Clario’s mission. He has demonstrated strong leadership to his teams and customers alike. We would also like to thank Joe for his leadership in successfully bringing together the two predecessor companies, ERT and BioClinica, to form Clario, successfully navigating the pandemic, and creating a strong team and culture in the new organization.”
Christopher will start in his new role in July and Joe will remain CEO during this transitionary period. Following his retirement, Joe will continue to support Clario as a member of the Board of Directors.
About Clario
Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry, allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Duncan Cantor
Sr. Director, PR and Thought Leadership
[email protected]